comp_molregno,act_standard_units,act_standard_type,act_activity_comment,act_bao_endpoint,act_type,ass_assay_id,ass_description,ass_assay_type,ass_assay_category,ass_chembl_id,doc_doi,doc_pubmed_id,doc_chembl_id,doc_title,doc_doc_type,doc_abstract,doc_patent_id,coms_canonical_smiles,comp_full_molformula,mold_chembl_id,act_0,act_1,act_2,act_3,act_4,act_5
BENAQGXYNPWMPR-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C24H26N6O3S/c1-28-10-6-18(7-11-28)33-21-5-4-16(14-27-21)30-23(34)29(22(31)24(30)8-3-9-24)17-12-20(32-2)19(13-25)26-15-17/h4-5,12,14-15,18H,3,6-11H2,1-2H3",0.60,-0.88,86.0,90.0,90.0,90.0,,
BJYQIDOKTISRPH-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C24H22F3N5O2S/c25-24(26,27)19-12-16(14-30-20(19)13-28)31-21(33)23(8-1-9-23)32(22(31)35)15-2-4-17(5-3-15)34-18-6-10-29-11-7-18/h2-5,12,14,18,29H,1,6-11H2",0.63,-0.70,90.0,90.0,100.0,100.0,,
BQVQKLJAAGDPIU-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, ","Entry 0: 924, Entry 1: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C18H12F3N5O2S/c19-18(20,21)12-6-11(9-23-13(12)7-22)25-15(28)17(4-1-5-17)26(16(25)29)10-2-3-14(27)24-8-10/h2-3,6,8-9H,1,4-5H2,(H,24,27)",0.75,-1.01,90.0,90.0,,,,
DJLIYOROHHWHGX-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C21H16F3N5O2S/c1-26-17(30)11-3-4-12-7-20(8-13(12)5-11)18(31)29(19(32)28(20)2)14-6-15(21(22,23)24)16(9-25)27-10-14/h3-6,10H,7-8H2,1-2H3,(H,26,30)",0.69,-1.18,90.0,90.0,,,,
FETCXMHYNSCFGK-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, ","Entry 0: 924, Entry 1: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C23H22F3N7O2S/c1-31-7-3-16(4-8-31)35-20-29-12-15(13-30-20)33-21(36)32(19(34)22(33)5-2-6-22)14-9-17(23(24,25)26)18(10-27)28-11-14/h9,11-13,16H,2-8H2,1H3",0.57,-0.84,90.0,90.0,,,,
GGSDYYYOPSLTGD-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C24H21F4N5O2S/c1-12(2)11-32-22(36)33(15-6-17(24(26,27)28)19(9-29)31-10-15)21(35)23(32)7-13-4-16(20(34)30-3)18(25)5-14(13)8-23/h4-6,10,12H,7-8,11H2,1-3H3,(H,30,34)",0.49,-1.30,90.0,90.0,,,,
GVVNCBCLKYSFQV-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-3-10-6-20(7-11(10)4-15(13)22)18(32)30(19(33)29(20)2)12-5-14(21(23,24)25)16(8-26)28-9-12/h3-5,9H,6-7H2,1-2H3,(H,27,31)",0.53,-1.31,90.0,90.0,,,,
GYLMJPQITNEESX-HSZRJFAPSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C24H20F4N4O2S/c1-12(2)32-22(35)31(16-5-4-13(11-29)18(8-16)24(26,27)28)21(34)23(32)9-14-6-17(20(33)30-3)19(25)7-15(14)10-23/h4-8,12H,9-10H2,1-3H3,(H,30,33)/t23-/m1/s1",0.51,-1.42,90.0,90.0,,,,
GYLMJPQITNEESX-QHCPKHFHSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C24H20F4N4O2S/c1-12(2)32-22(35)31(16-5-4-13(11-29)18(8-16)24(26,27)28)21(34)23(32)9-14-6-17(20(33)30-3)19(25)7-15(14)10-23/h4-8,12H,9-10H2,1-3H3,(H,30,33)/t23-/m0/s1",0.51,-1.42,90.0,90.0,,,,
GYLMJPQITNEESX-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C24H20F4N4O2S/c1-12(2)32-22(35)31(16-5-4-13(11-29)18(8-16)24(26,27)28)21(34)23(32)9-14-6-17(20(33)30-3)19(25)7-15(14)10-23/h4-8,12H,9-10H2,1-3H3,(H,30,33)",0.51,-1.42,90.0,90.0,,,,
HBZOZSIQTBAFAL-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, ","Entry 0: 924, Entry 1: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C19H13F3N4O2S/c20-19(21,22)14-8-12(10-24-15(14)9-23)25-16(28)18(6-1-7-18)26(17(25)29)11-2-4-13(27)5-3-11/h2-5,8,10,27H,1,6-7H2",0.75,-0.83,90.0,90.0,,,,
HIYUFTVAWMTBHU-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,ANTAGONIST,"Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C20H14F3N5O2S/c1-25-16(29)10-2-3-11-6-19(7-12(11)4-10)17(30)28(18(31)27-19)13-5-14(20(21,22)23)15(8-24)26-9-13/h2-5,9H,6-7H2,1H3,(H,25,29)(H,27,31)",0.69,-1.27,35.0,52.0,,,,
HMOFOYJGYHPOON-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C25H21F4N5O2S/c1-31-21(35)17-6-13-9-24(10-14(13)7-19(17)26)22(36)33(23(37)34(24)15-4-2-3-5-15)16-8-18(25(27,28)29)20(11-30)32-12-16/h6-8,12,15H,2-5,9-10H2,1H3,(H,31,35)",0.48,-1.20,90.0,90.0,,,,
HZOGAMMPPUPHGK-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C23H17F4N5O2S/c1-29-19(33)15-4-11-7-22(8-12(11)5-17(15)24)20(34)31(21(35)32(22)13-2-3-13)14-6-16(23(25,26)27)18(9-28)30-10-14/h4-6,10,13H,2-3,7-8H2,1H3,(H,29,33)",0.51,-1.26,90.0,90.0,,,,
IZKSMIBPGSWAMO-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, Entry 4: BAO_0000179, Entry 5: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, Entry 4: ANTAGONIST, Entry 5: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, Entry 4: 121087, Entry 5: 121087, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 4: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 5: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, Entry 4: 34422225, Entry 5: 34422225, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, Entry 4: 1252, Entry 5: 1252, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, Entry 4: 10.1021/acsmedchemlett.1c00032, Entry 5: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, Entry 4: CHEMBL4834497, Entry 5: CHEMBL4834497, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 4: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 5: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 4: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 5: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 4: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 5: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C25H24F3N5O2S/c1-31-11-7-19(8-12-31)35-18-5-3-16(4-6-18)33-23(36)32(22(34)24(33)9-2-10-24)17-13-20(25(26,27)28)21(14-29)30-15-17/h3-6,13,15,19H,2,7-12H2,1H3",0.56,-0.88,90.0,90.0,90.0,90.0,100.0,100.0
JQULNFLHCKLUKJ-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C25H27N5O3S/c1-28-12-8-20(9-13-28)33-19-6-4-17(5-7-19)30-24(34)29(23(31)25(30)10-3-11-25)18-14-22(32-2)21(15-26)27-16-18/h4-7,14,16,20H,3,8-13H2,1-2H3",0.61,-0.70,90.0,90.0,100.0,100.0,,
KJNFUKYWWSXYPS-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C22H17F3N4O2S/c1-27-18(30)12-3-4-13-9-21(10-15(13)7-12)19(31)29(20(32)28(21)2)16-6-5-14(11-26)17(8-16)22(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,30)",0.70,-1.27,90.0,90.0,,,,
MXISWALVVXLANL-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C22H17F3N4O3/c1-27-18(30)12-3-4-13-9-21(10-15(13)7-12)19(31)29(20(32)28(21)2)16-6-5-14(11-26)17(8-16)22(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,30)",0.72,-1.27,90.0,90.0,,,,
NCXUTHWYFBPSNO-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C23H22ClN5O2S/c24-19-12-16(14-27-20(19)13-25)28-21(30)23(8-1-9-23)29(22(28)32)15-2-4-17(5-3-15)31-18-6-10-26-11-7-18/h2-5,12,14,18,26H,1,6-11H2",0.68,-0.66,90.0,90.0,90.0,100.0,,
OUEHJEYKNYQVRC-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C23H21F3N6O2S/c24-23(25,26)17-10-15(13-29-18(17)11-27)31-20(33)22(6-1-7-22)32(21(31)35)14-2-3-19(30-12-14)34-16-4-8-28-9-5-16/h2-3,10,12-13,16,28H,1,4-9H2",0.63,-0.88,90.0,90.0,100.0,100.0,,
PMIXDFGOWWPZCA-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C23H24N6O2S/c1-15-11-17(14-26-19(15)12-24)28-21(30)23(7-2-8-23)29(22(28)32)16-3-4-20(27-13-16)31-18-5-9-25-10-6-18/h3-4,11,13-14,18,25H,2,5-10H2,1H3",0.71,-0.79,90.0,90.0,100.0,100.0,,
QWOXNKRFQAABQG-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, ","Entry 0: 924, Entry 1: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C24H23F3N6O2S/c1-31-9-5-17(6-10-31)35-20-4-3-15(13-30-20)33-22(36)32(21(34)23(33)7-2-8-23)16-11-18(24(25,26)27)19(12-28)29-14-16/h3-4,11,13-14,17H,2,5-10H2,1H3",0.57,-1.05,90.0,90.0,,,,
QWTUBLVEMRHUOG-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, ","Entry 0: 924, Entry 1: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C22H20F3N7O2S/c23-22(24,25)16-8-13(10-28-17(16)9-26)31-18(33)21(4-1-5-21)32(20(31)35)14-11-29-19(30-12-14)34-15-2-6-27-7-3-15/h8,10-12,15,27H,1-7H2",0.63,-0.66,67.0,85.0,,,,
RPWTVJGAPYBZJM-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C25H22F4N4O2S/c1-13(2)12-32-23(36)33(17-5-4-14(11-30)19(8-17)25(27,28)29)22(35)24(32)9-15-6-18(21(34)31-3)20(26)7-16(15)10-24/h4-8,13H,9-10,12H2,1-3H3,(H,31,34)",0.49,-1.40,90.0,90.0,,,,
UAQHIEJWSYVSST-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C26H23F4N5O2S/c1-32-22(36)18-7-14-10-25(11-15(14)8-20(18)27)23(37)34(24(38)35(25)16-5-3-2-4-6-16)17-9-19(26(28,29)30)21(12-31)33-13-17/h7-9,13,16H,2-6,10-11H2,1H3,(H,32,36)",0.46,-1.17,90.0,90.0,,,,
UPXGPACRTHMNQJ-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C21H15F3N4O2S/c1-26-17(29)11-2-3-12-8-20(9-14(12)6-11)18(30)28(19(31)27-20)15-5-4-13(10-25)16(7-15)21(22,23)24/h2-7H,8-9H2,1H3,(H,26,29)(H,27,31)",0.70,-1.37,80.0,90.0,,,,
VHOSAFVOARVEOA-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, ","Entry 0: 924, Entry 1: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C24H23F3N6OS/c25-24(26,27)19-12-18(14-30-20(19)13-28)32-21(34)23(6-1-7-23)33(22(32)35)17-4-2-16(3-5-17)15-31-10-8-29-9-11-31/h2-5,12,14,29H,1,6-11,15H2",0.64,-1.20,90.0,90.0,,,,
VUBVBCFCFVJNCF-JOCHJYFZSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C23H19F4N5O2S/c1-11(2)32-21(35)31(14-6-16(23(25,26)27)18(9-28)30-10-14)20(34)22(32)7-12-4-15(19(33)29-3)17(24)5-13(12)8-22/h4-6,10-11H,7-8H2,1-3H3,(H,29,33)/t22-/m1/s1",0.51,-1.32,90.0,90.0,,,,
VUBVBCFCFVJNCF-QFIPXVFZSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C23H19F4N5O2S/c1-11(2)32-21(35)31(14-6-16(23(25,26)27)18(9-28)30-10-14)20(34)22(32)7-12-4-15(19(33)29-3)17(24)5-13(12)8-22/h4-6,10-11H,7-8H2,1-3H3,(H,29,33)/t22-/m0/s1",0.51,-1.32,90.0,90.0,,,,
VUBVBCFCFVJNCF-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C23H19F4N5O2S/c1-11(2)32-21(35)31(14-6-16(23(25,26)27)18(9-28)30-10-14)20(34)22(32)7-12-4-15(19(33)29-3)17(24)5-13(12)8-22/h4-6,10-11H,7-8H2,1-3H3,(H,29,33)",0.51,-1.32,90.0,90.0,,,,
WNSOXYLPJNGFAT-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C24H22F3N5O2S/c1-31-22(35)32(16-9-19(24(25,26)27)20(12-28)30-13-16)21(33)23(31)10-14-2-3-18(8-15(14)11-23)34-17-4-6-29-7-5-17/h2-3,8-9,13,17,29H,4-7,10-11H2,1H3",0.65,-0.66,90.0,90.0,,,,
WXCXUHSOUPDCQV-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 121087, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 34422225, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 1252, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4834497, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",0.55,-1.50,86.0,90.0,90.0,100.0,,
YBQSIUJDCMFXJD-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C24H19F4N5O2S/c1-30-20(34)16-5-12-8-23(9-13(12)6-18(16)25)21(35)32(22(36)33(23)14-3-2-4-14)15-7-17(24(26,27)28)19(10-29)31-11-15/h5-7,11,14H,2-4,8-9H2,1H3,(H,30,34)",0.50,-1.21,90.0,90.0,,,,
ZCZLQDQOPOVWHH-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, ","Entry 0: 121087, Entry 1: 121087, ","Entry 0: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, Entry 1: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control, ",,,"Entry 0: 34422225, Entry 1: 34422225, ","Entry 0: 1252, Entry 1: 1252, ","Entry 0: 10.1021/acsmedchemlett.1c00032, Entry 1: 10.1021/acsmedchemlett.1c00032, ","Entry 0: CHEMBL4834497, Entry 1: CHEMBL4834497, ","Entry 0: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 1: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., Entry 1: Zhang Z, Connolly PJ, Trabalón Escolar L, Rocaboy C, Pande V, Meerpoel L, Lim HK, Branch JR, Ondrus J, Hickson I, Bush TL, Bischoff JR, Bignan G., ","Entry 0: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 1: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ","InChI=1S/C22H16F4N4O2S/c1-28-18(31)15-5-12-8-21(9-13(12)6-17(15)23)19(32)30(20(33)29(21)2)14-4-3-11(10-27)16(7-14)22(24,25)26/h3-7H,8-9H2,1-2H3,(H,28,31)",0.53,-1.42,90.0,90.0,,,,
ZXSHKSIAPKOCNB-UHFFFAOYSA-N,%,Imax,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, Entry 3: BAO_0000179, ",Imax,"Entry 0: ANTAGONIST, Entry 1: ANTAGONIST, Entry 2: ANTAGONIST, Entry 3: ANTAGONIST, ","Entry 0: 120461, Entry 1: 120461, Entry 2: 120461, Entry 3: 120461, ","Entry 0: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 1: Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control, ",,,"Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, ","Entry 0: 924, Entry 1: 924, Entry 2: 924, Entry 3: 924, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., ","Entry 0: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 1: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 2: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., Entry 3: Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G., ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., ","InChI=1S/C22H21ClN6O2S/c23-17-10-15(13-26-18(17)11-24)28-20(30)22(6-1-7-22)29(21(28)32)14-2-3-19(27-12-14)31-16-4-8-25-9-5-16/h2-3,10,12-13,16,25H,1,4-9H2",0.68,-0.85,90.0,90.0,100.0,100.0,,
